12 March 2020
Leading Russian drugmakers and foreign companies operating in the local market have called on the Russian government to change the existing rules for public procurements of drugs in Russia and to optimize the existing state measures for the support of the domestic pharmaceutical companies, according to recent statements, made by representatives of producers, reports The Pharma Letter.
According to Victor Dmitriev, head of the Association of Russian Pharmaceutical Manufacturers, last year, due to imperfection of the Russian legislation in the field of drug public procurements, at least 65,000 auctions across the country to buy drugs for state needs were cancelled.
According to producers, there is a need to design a separate regulation of public procurements of drugs in Russia, that will provide an opportunity for local hospitals to use a more flexible approach during the choice of their suppliers and to achieve bigger savings during procurements.
Mr Dmitriev also noted that the Russian pharmaceutical market needs a single regulator, whose activities will contribute to its better stabilization also in regard to pricing.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024